Coherus Oncology, Inc. (CHRS) has a significantly negative Return on Invested Capital (ROIC) of -117.17%, indicating challenges in generating returns on its invested capital.Atara Biotherapeutics, Inc. (ATRA) showcases a strong financial position with a ROIC of 36.19% and a Weighted Average Cost of Capital (WACC) of 6.36%, highlighting efficient capital utilization.Comparatively, companies like FibroGen, Inc. (FGEN) and MacroGenics, Inc. (MGNX) also face challenges with negative ROIC to WACC ratios, indicat ...

uniQure N.V. (NASDAQ:QURE) has a Return on Invested Capital (ROIC) of -23.80% and a Weighted Average Cost of Capital (WACC) of 11.72%, indicating it generates returns below its cost of capital.REGENXBIO Inc. and Voyager Therapeutics, Inc. show even lower efficiency in generating returns over their cost of capital compared to uniQure.Blueprint Medicines Corporation exhibits the highest potential for improvement among the peers, with a ROIC to WACC ratio closest to breaking even.uniQure N.V. (NASDAQ:QURE) is ...

Core Insights - Verra Mobility Corporation (NASDAQ:VRRM) provides smart transportation solutions, focusing on toll and violations management, as well as commercial fleet services [1] - The company operates in a competitive landscape with peers such as International Money Express, Inc. (IMXI), Option Care Health, Inc. (OPCH), and R1 RCM Inc. (RCM) [1] Financial Performance - Verra Mobility has a Return on Invested Capital (ROIC) of 4.72% and a Weighted Average Cost of Capital (WACC) of 5.82%, resulting in a ROIC to WACC ratio of 0.81, indicating inefficiencies in investment strategies [2][6] - International Money Express, Inc. (IMXI) shows a strong financial performance with a ROIC of 14.18% and a WACC of 6.98%, leading to a ROIC to WACC ratio of 2.03, showcasing strong capital efficiency [3][6] - Option Care Health, Inc. (OPCH) has a ROIC of 9.20% and a WACC of 6.87%, resulting in a ROIC to WACC ratio of 1.34, indicating returns above its cost of capital [4][6] - R1 RCM Inc. (RCM) has a ROIC of 0.96% and a WACC of 7.69%, leading to a ROIC to WACC ratio of 0.12, indicating significant inefficiencies in generating returns [5][6]

Greenpro Capital Corp. (NASDAQ:GRNQ) is a company that provides financial services, including business consulting and corporate advisory services. It operates primarily in the Asia-Pacific region. The company is involved in a variety of sectors, including real estate, technology, and finance. Greenpro's competitors include companies like Farmmi, Inc., and Oxbridge Re Holdings Limited.In evaluating Greenpro's financial performance, the Return on Invested Capital (ROIC) is a critical metric. Greenpro's ROIC s ...

Core Insights - Avadel Pharmaceuticals plc is focused on developing innovative medicines for sleep disorders, particularly narcolepsy, and operates in a competitive landscape with peers like Eyenovia, Aquestive Therapeutics, Clearside Biomedical, and Intra-Cellular Therapies [1] Financial Performance - Avadel's Return on Invested Capital (ROIC) is 0.86%, which is significantly lower than its Weighted Average Cost of Capital (WACC) of 10.91%, indicating inefficiency in capital use [2] - Eyenovia, Inc. has a ROIC of -33.32% and a WACC of 17.12%, resulting in a ROIC to WACC ratio of -1.94 [3] - Aquestive Therapeutics, Inc. shows a ROIC of -69.51% against a WACC of 13.24%, leading to a ROIC to WACC ratio of -5.25 [3] - Clearside Biomedical, Inc. presents a ROIC of -177.13% and a WACC of 18.30%, resulting in a ROIC to WACC ratio of -9.67 [4] - Intra-Cellular Therapies, Inc. has a ROIC of -8.23% and a WACC of 5.90%, with a ROIC to WACC ratio of -1.39, indicating slightly better capital efficiency compared to peers [4] Industry Challenges - The analysis indicates a challenging environment for biopharmaceutical companies, as none are generating sufficient returns to cover their cost of capital, highlighting the need for improved capital efficiency to enhance investor confidence [5]

Core Insights - Dime Community Bancshares, Inc. (NASDAQ:DCOM) operates primarily in the New York metropolitan area, providing a range of personal and business banking services, and competes with regional banks such as Flushing Financial Corporation and Brookline Bancorp [1] - DCOM's Return on Invested Capital (ROIC) is 2.15%, while its Weighted Average Cost of Capital (WACC) is 15.71%, resulting in a ROIC to WACC ratio of 0.137, indicating inefficiency in capital use [2][5] - Comparative analysis shows that CVB Financial Corp. (CVBF) and City Holding Company (CHCO) have more favorable ROIC to WACC ratios, suggesting they are more efficient in generating returns than DCOM [4][5] Financial Efficiency Comparison - Flushing Financial Corporation (FFIC) has a negative ROIC of -12.80% and a WACC of 16.70%, leading to a ROIC to WACC ratio of -0.767, indicating greater inefficiency than DCOM [3] - Brookline Bancorp (BRKL) and OceanFirst Financial Corp. (OCFC) also show negative ROIC to WACC ratios of -0.082 and 0.012, respectively, further highlighting inefficiencies in these institutions [3] - In contrast, CVB Financial Corp. (CVBF) has a ROIC of 5.15% and a WACC of 9.05%, resulting in a ratio of 0.570, while CHCO has a ROIC of 18.41% and a WACC of 7.79%, achieving a ratio of 2.361, indicating superior efficiency [4]

Core Insights - i3 Verticals, Inc. is a technology and integrated payments company serving small and medium-sized businesses across various sectors, including education, healthcare, and public sector [1] - The company faces competition in the payment processing and technology sectors [1] Financial Performance - i3 Verticals has a Return on Invested Capital (ROIC) of 0.26%, indicating minimal efficiency in generating returns from investments [2][6] - The company's Weighted Average Cost of Capital (WACC) is 8.55%, suggesting that it pays a high rate for its capital [2][6] - The ROIC to WACC ratio of 0.03 indicates that i3 Verticals struggles to generate returns that exceed its cost of capital [2] Peer Comparison - International Money Express, Inc. (IMXI) and OneSpan Inc. (OSPN) have a ROIC to WACC ratio of 2.06, demonstrating superior capital utilization compared to i3 Verticals [3][6] - nLIGHT, Inc. (LASR) and Repay Holdings Corporation (RPAY) exhibit negative ROIC to WACC ratios of -1.25 and -1.34, respectively, indicating challenges in covering their cost of capital [4][6] - PC Connection, Inc. (CNXN) has a ROIC to WACC ratio of 1.06, suggesting a moderate level of efficiency in generating returns above its cost of capital [5]

Core Insights - Verra Mobility Corporation specializes in smart transportation solutions, including toll and violations management, and commercial fleet services, operating in a competitive landscape with peers like International Money Express, Inc., Option Care Health, Inc., and R1 RCM Inc. [1] Financial Performance - Verra Mobility's Return on Invested Capital (ROIC) is 4.72%, which is lower than its Weighted Average Cost of Capital (WACC) of 5.78%, resulting in a ROIC to WACC ratio of 0.82, indicating insufficient returns to cover its cost of capital [2] - International Money Express, Inc. demonstrates strong capital efficiency with a ROIC of 14.18% and a WACC of 6.93%, leading to a ROIC to WACC ratio of 2.05, highlighting effective capital utilization compared to Verra Mobility [3] - Option Care Health, Inc. shows efficient capital use with a ROIC of 9.20% and a WACC of 6.85%, resulting in a favorable ROIC to WACC ratio of 1.34, indicating effective returns on invested capital [4] - R1 RCM Inc. faces similar challenges as Verra Mobility, with a ROIC of 0.96% and a WACC of 7.69%, leading to a low ROIC to WACC ratio of 0.12, indicating significant inefficiencies in capital utilization [5]

Company Overview - Celcuity Inc. is a biotechnology company focused on developing diagnostic tests for cancer patients, aiming to identify effective therapies tailored to individual needs [1] Financial Performance - Celcuity's Return on Invested Capital (ROIC) is -36.46%, significantly lower than its Weighted Average Cost of Capital (WACC) of 4.88%, indicating negative returns on invested capital [2] - The ROIC to WACC ratio for Celcuity is -7.47, showing that returns are well below the cost of capital [2] Peer Comparison - Crinetics Pharmaceuticals has a ROIC of -42.35% and a WACC of 4.55%, resulting in a ROIC to WACC ratio of -9.30, which is less negative than Celcuity's, suggesting it is closer to covering its cost of capital [3] - Evelo Biosciences has a ROIC of -201.37% and a WACC of 9.04%, leading to a ROIC to WACC ratio of -22.28, indicating a more severe situation than Celcuity [4] - Scholar Rock Holding Corporation and Cue Biopharma report negative ROICs of -101.98% and -151.57%, respectively, with ROIC to WACC ratios of -15.01 and -15.31, reflecting a common trend among clinical-stage biotech companies facing negative returns due to high R&D investments and limited revenue generation [5]

Core Insights - Vivid Seats Inc. operates in a competitive online ticket marketplace but faces significant financial challenges, particularly in capital efficiency [1][5] Financial Performance - Vivid Seats has a Return on Invested Capital (ROIC) of -61.41%, which is substantially lower than its Weighted Average Cost of Capital (WACC) of 4.95%, indicating insufficient returns to cover capital costs [2][5] - The ROIC to WACC ratio for Vivid Seats is -12.41, further emphasizing its inefficiency in capital utilization [2] - In contrast, Sovos Brands, Inc. has a positive ROIC of 5.54% and a WACC of 5.21%, suggesting effective capital use and strong financial health [3][5] - Bowlero Corp. and CareMax, Inc. both report negative ROICs of -114.39% and -117.47%, respectively, indicating similar challenges in covering their capital costs as Vivid Seats [4][5] - Stagwell Inc. shows a slightly better scenario with a positive ROIC of 3.11%, although it still does not meet its WACC of 4.11%, indicating room for improvement [4]